The debilitating loss of smell, a pervasive and often overlooked symptom for individuals battling chronic rhinosinusitis with nasal polyps (CRSwNP), is showing promising signs of recovery with the therapeutic agent tezepelumab. New findings from the pivotal WAYPOINT trial, detailed in the International Forum of Allergy & Rhinology, reveal that tezepelumab not only addresses the underlying inflammation but also leads to significant and enduring restoration of olfactory function. This breakthrough offers a crucial new avenue for improving the quality of life for a patient population severely impacted by this sensory deficit.
The Profound Impact of Olfactory Dysfunction in CRSwNP
Loss of smell, medically termed anosmia or hyposmia, extends far beyond a mere inconvenience. For patients with CRSwNP, it can lead to a cascade of negative consequences affecting daily life. The ability to discern scents is intricately linked to enjoyment of food, the capacity to detect dangers like gas leaks or spoiled food, and even the nuances of social interaction. The erosion of this sense can lead to social isolation, a diminished appetite, and a general reduction in overall well-being. The chronic inflammatory processes characteristic of CRSwNP, particularly those driven by Type 2 inflammation, are increasingly understood to play a direct role in damaging the olfactory epithelium – the delicate tissue responsible for detecting odors. This damage can be both structural, due to polyp obstruction, and functional, due to the inflammatory milieu.
Tezepelumab: A Novel Approach to Type 2 Inflammation
Tezepelumab represents a significant advancement in the treatment of severe, uncontrolled CRSwNP by targeting thymic stromal lymphopoietin (TSLP). TSLP is a critical upstream epithelial cytokine that orchestrates a broad spectrum of inflammatory pathways implicated in Type 2-driven diseases, including CRSwNP. By blocking TSLP, tezepelumab aims to disrupt the inflammatory cascade at its source, thereby addressing the multifaceted pathology of the condition. This mechanism of action is particularly relevant to olfactory dysfunction, as TSLP is known to contribute to the inflammatory environment that compromises the olfactory system.
The WAYPOINT Trial: Rigorous Evaluation of Olfactory Outcomes
The WAYPOINT trial, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, was designed to rigorously assess the efficacy of tezepelumab in adults with uncontrolled CRSwNP. The study enrolled 408 patients, with 203 individuals receiving tezepelumab at a dose of 210 mg subcutaneously every four weeks, and 205 receiving a placebo over a 52-week treatment period. A key focus of this extensive trial was the comprehensive evaluation of olfactory function, employing a suite of validated patient-reported outcome measures and objective olfactory tests.
The study’s primary objective was to determine if tezepelumab could significantly improve loss of smell in this patient cohort. The assessment of smell outcomes was multifaceted, incorporating:
- Nasal Polyposis Symptom Diary (NPSD): A daily diary allowing patients to track the severity of specific CRSwNP symptoms, including a dedicated item for loss of smell. This provided granular, real-time data on symptom fluctuations.
- University of Pennsylvania Smell Identification Test (UPSIT): A widely recognized, standardized test that assesses a patient’s ability to identify a range of common odors. This offered an objective measure of olfactory identification capacity.
- Sino-Nasal Outcome Test (SNOT-22): A comprehensive questionnaire evaluating the impact of sinonasal disease on quality of life, which includes specific items related to smell and taste dysfunction.
- UPSIT-defined anosmia prevalence: The proportion of patients who met the criteria for complete loss of smell (anosmia) as determined by UPSIT scores.
Early and Sustained Olfactory Recovery
The results from the WAYPOINT trial are compelling, demonstrating that tezepelumab delivers both rapid and lasting improvements in olfactory function. At baseline, patients in both the tezepelumab and placebo groups exhibited severe smell impairment, with comparable mean NPSD loss-of-smell scores (2.9), mean UPSIT scores (13.1 for tezepelumab, 11.9 for placebo), and mean SNOT-22 smell/taste item scores (4.7).
The therapeutic benefits of tezepelumab became apparent remarkably early in the treatment course. Differences in daily NPSD loss-of-smell scores favoring tezepelumab were observed as early as day seven of treatment, with a least-squares mean difference of -0.08 (nominal P<0.01). This indicates that patients receiving tezepelumab began to report an improvement in their sense of smell within the first week of therapy.
By week four of treatment, the observed improvements widened significantly across all measured olfactory endpoints. Tezepelumab demonstrated a greater improvement compared to placebo in biweekly NPSD loss-of-smell scores (difference of -0.36), UPSIT scores (difference of 6.03), and SNOT-22 smell/taste item scores (difference of -1.01). These findings underscore the early and impactful nature of tezepelumab’s effect on restoring olfactory sensation.
Crucially, these benefits were not transient. The improvements in smell function were sustained throughout the entire 52-week treatment period. At week 52, the treatment differences remained substantial, with a difference of -1.01 for NPSD, an impressive 9.50 for UPSIT scores, and -1.90 for SNOT-22 smell/taste scores. All reported P-values for these endpoints were nominal, reflecting the exploratory nature of some analyses within the trial but highlighting a strong trend of efficacy.
Remarkable Reduction in Anosmia and Increase in Normosmia
Perhaps one of the most striking findings is the dramatic reduction in the prevalence of anosmia among patients treated with tezepelumab. At week four, the proportion of patients classified as anosmic based on UPSIT data was significantly lower in the tezepelumab group (43.0%) compared to the placebo group (80.3%). This gap widened further by week 52, with anosmia affecting 31.5% of tezepelumab recipients versus 75.8% of those on placebo.
Conversely, tezepelumab treatment led to a notable increase in the proportion of patients achieving normosmia – a normal sense of smell. While no patients in the placebo group achieved normosmia by week 52 (compared to 2.3% from baseline, potentially reflecting spontaneous recovery or placebo effect), a significant 10.7% of patients treated with tezepelumab regained a normal sense of smell by the end of the study. This represents a substantial restoration of olfactory function for a considerable segment of the treated population.
Broad Applicability and Subgroup Analysis
The positive impact of tezepelumab on olfactory function was consistent across a range of prespecified patient subgroups. This included variations in sex, history of prior nasal polyp surgery, disease duration, geographic region, and the presence of comorbidities such as asthma, aspirin-exacerbated respiratory disease (AERD), and allergic rhinitis. This broad efficacy suggests that tezepelumab’s benefits are not confined to specific patient profiles and can be expected across a diverse CRSwNP population.
Study Limitations and Future Directions
While the findings are robust, the researchers acknowledge certain limitations. Some analyses were post hoc, meaning they were not pre-specified in the original trial protocol. Additionally, many endpoints utilized nominal testing, which, while indicative of strong trends, warrants cautious interpretation without further confirmatory statistical analysis. The reliance on the UPSIT test, which primarily assesses odor identification, also means that aspects of olfactory function such as the detection threshold (the faintest smell detectable) and olfactory discrimination (the ability to differentiate between similar smells) were not directly evaluated. Future research could incorporate more comprehensive olfactory testing batteries to provide an even more detailed understanding of tezepelumab’s effects.
Expert Commentary and Broader Implications
The findings of the WAYPOINT trial are being met with considerable enthusiasm from the medical community. Dr. Ashoke Khanwalkar, MD, commented on the significance of these results, stating, "Loss of olfaction is one of the most troubling symptoms for patients suffering from CRSwNP. This is thought to occur not only due to the obstruction caused by the presence of polyps but also due to inflammation in the epithelium itself." He further noted the historical context: "Before the approval of tezepelumab for CRSwNP, dupilumab appeared to provide the greatest benefit for improvement in olfaction for patients with CRSwNP, rivaling surgery. Tezepelumab is a relatively new agent targeting TSLP."
The emergence of tezepelumab as a viable option for improving olfaction in CRSwNP patients is a significant development. It offers another therapeutic strategy alongside existing treatments, which historically have included surgical intervention and, more recently, biologic therapies like dupilumab. The ability of tezepelumab to address the upstream inflammatory driver TSLP suggests a potentially broad impact on the inflammatory cascade that underlies CRSwNP, extending beyond olfactory improvements to other key disease manifestations.
A Timeline of Discovery and Treatment Evolution
The journey towards understanding and treating CRSwNP-related olfactory dysfunction has been a long one. For decades, nasal polyps were primarily viewed as a surgical problem, with surgery offering some relief, albeit often temporary, for smell loss. The advent of targeted anti-inflammatory therapies marked a paradigm shift.
- Early 2000s: Increased understanding of the role of Type 2 inflammation in CRSwNP.
- Mid-2010s: Development and initial trials of biologic agents targeting key inflammatory pathways. Dupilumab, an interleukin-4 receptor alpha antagonist, began showing significant promise in improving sinonasal symptoms, including olfaction.
- Late 2010s – Early 2020s: Tezepelumab, targeting the upstream cytokine TSLP, undergoes extensive clinical development. The WAYPOINT trial specifically investigates its efficacy in CRSwNP.
- 2021: Tezepelumab receives regulatory approval for the treatment of severe asthma, signaling its potential in broader Type 2 inflammatory diseases.
- 2023-2024: Regulatory submissions and approvals for tezepelumab in CRSwNP commence in various regions, based on pivotal trial data like that from WAYPOINT.
- Present: The WAYPOINT study’s detailed findings on olfactory outcomes are published, providing robust evidence for tezepelumab’s impact on smell restoration.
The Broader Impact on Patient Care
The implications of these findings for the management of CRSwNP are substantial. For patients who have lived for years, or even decades, with a diminished or absent sense of smell, the prospect of regaining this vital sense is life-altering. Tezepelumab offers a non-surgical option that not only tackles the underlying inflammation but also demonstrably restores olfactory function. This can lead to improved nutritional intake, enhanced safety awareness, and a significant uplift in psychological well-being and social engagement.
As the understanding of CRSwNP evolves, so too do the therapeutic strategies. Tezepelumab’s ability to impact TSLP, a master regulator of Type 2 inflammation, suggests a potent and comprehensive approach to managing this complex disease. The sustained improvements observed in the WAYPOINT trial indicate that this is not a fleeting effect but a lasting restoration of a crucial sensory experience. This development promises to redefine expectations for patients with CRSwNP, offering renewed hope for a richer, safer, and more enjoyable life.
Citation:
Mullol J, et al. Early and sustained improvements in sense of smell with tezepelumab treatment in patients with chronic rhinosinusitis with nasal polyps (WAYPOINT). Int Forum Allergy Rhinol. 2026;16:484-494. doi:10.1002/alr.70090
